Spirometry study for people with CVID on IG therapy
Part of Immune system & allergy clinical trials.
This trial looks at how breathing tests (spirometry) can help guide treatment decisions for people with CVID and airway disease who are already on immune globulin (IG) therapy. It may help your care team better monitor lung function using a specific breathing-test pattern.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have common variable immune deficiency (CVID).
- You are already taking IG therapy (including Hizentra if available) and it has been stable for at least 3 months.
- Your spirometry result for FEF25–75% is between 50% and 80% of what is expected for your age.
- You are at least 21 years old and able to do spirometry breathing tests.
- You do not have major excluded conditions like certain infections (like TB) or specific lung/heart diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific type of immune cell in people with Common Variable Immune Deficiency (CVID). It aims to learn more about how these cells behave and may help guide better treatments for this condition.
This Phase 2 trial tests abatacept to improve a specific type of lung disease in children with common variable immunodeficiency (CVID). It aims to slow or reduce ongoing lung changes seen on CT scans while they continue their usual immune “replacement” therapy.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
This trial tests a new intravenous immunoglobulin (IVIG) treatment for patients with primary immunodeficiency diseases, such as common variable immune deficiency (CVID) or X-linked agammaglobulinemia (XLA). It aims to see if this medicine is safe and works well to prevent infections.
Hear when a new Common Variable Immunodeficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.